CA3172596A1 - Pulmonary fibrosis medicine containing pyrazole derivative - Google Patents

Pulmonary fibrosis medicine containing pyrazole derivative Download PDF

Info

Publication number
CA3172596A1
CA3172596A1 CA3172596A CA3172596A CA3172596A1 CA 3172596 A1 CA3172596 A1 CA 3172596A1 CA 3172596 A CA3172596 A CA 3172596A CA 3172596 A CA3172596 A CA 3172596A CA 3172596 A1 CA3172596 A1 CA 3172596A1
Authority
CA
Canada
Prior art keywords
pyrazol
pyridin
hydrochloride salt
compound
pheny1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3172596A
Other languages
English (en)
French (fr)
Inventor
Sung Hwan Moon
Soo Jin Lee
Hyunkyung Yu
Yoo-Kyung GOH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
APTABIO THERAPEUTICS Inc
Original Assignee
APTABIO THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020210036863A external-priority patent/KR102386097B1/ko
Application filed by APTABIO THERAPEUTICS Inc filed Critical APTABIO THERAPEUTICS Inc
Publication of CA3172596A1 publication Critical patent/CA3172596A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3172596A 2020-04-13 2021-03-23 Pulmonary fibrosis medicine containing pyrazole derivative Pending CA3172596A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20200044598 2020-04-13
KR10-2020-0044598 2020-04-13
KR10-2021-0036863 2021-03-22
KR1020210036863A KR102386097B1 (ko) 2020-04-13 2021-03-22 피라졸 유도체의 폐섬유증 치료제
PCT/KR2021/003537 WO2021210799A1 (ko) 2020-04-13 2021-03-23 피라졸 유도체의 폐섬유증 치료제

Publications (1)

Publication Number Publication Date
CA3172596A1 true CA3172596A1 (en) 2021-10-21

Family

ID=78083982

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3172596A Pending CA3172596A1 (en) 2020-04-13 2021-03-23 Pulmonary fibrosis medicine containing pyrazole derivative

Country Status (12)

Country Link
US (1) US12616684B2 (cg-RX-API-DMAC7.html)
EP (1) EP4137134A4 (cg-RX-API-DMAC7.html)
JP (1) JP7539485B2 (cg-RX-API-DMAC7.html)
KR (2) KR102567012B1 (cg-RX-API-DMAC7.html)
CN (1) CN115427039B (cg-RX-API-DMAC7.html)
AU (1) AU2021255160B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022020649A2 (cg-RX-API-DMAC7.html)
CA (1) CA3172596A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002642A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014273A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022012726A (cg-RX-API-DMAC7.html)
WO (1) WO2021210799A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240822A1 (es) 2021-03-22 2024-04-18 Neurocrine Biosciences Inc Inhibidores de vmat2 y metodos de uso

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040094464A (ko) * 2003-05-02 2004-11-10 학교법인 이화학당 피리디닐 피라졸 유도체
RU2012110580A (ru) 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Способы скрининга in vivo
KR101280160B1 (ko) 2009-09-02 2013-06-28 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
KR101302315B1 (ko) * 2011-07-19 2013-08-30 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물
KR101633957B1 (ko) * 2012-08-27 2016-06-27 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
WO2015195684A2 (en) * 2014-06-16 2015-12-23 University Of Rochester Small molecule anti-scarring agents
EP3411045A4 (en) * 2016-02-02 2020-01-08 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Chemicals and methods to prevent and treat tgf-beta mediated activation of fibroblasts to reduce and treat cancer and fibrosis
WO2017192304A1 (en) 2016-05-02 2017-11-09 Inception 1, Inc. Arylcarboxamides and uses thereof
EP3573614B1 (en) 2017-01-27 2024-11-20 Genfit Pharmaceutical compositions for combination therapy
KR101821593B1 (ko) * 2017-02-23 2018-01-25 압타바이오 주식회사 안질환 치료제
SG11201907673YA (en) 2017-03-13 2019-09-27 Genfit Pharmaceutical compositions for combination therapy
CA3058542A1 (en) 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
KR101856444B1 (ko) 2017-04-20 2018-05-10 압타바이오 주식회사 3-페닐-4-프로필-1-(피리딘-2-일)-1h-피라졸-5-올 염산염의 신규 결정형 고체 화합물
KR101840702B1 (ko) * 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
KR20210036863A (ko) 2018-08-01 2021-04-05 니폰 가야꾸 가부시끼가이샤 N-알킬기를 갖는 방향족 아민 수지, 경화성 수지 조성물 및 그 경화물
EP3628669A1 (en) * 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
KR102207340B1 (ko) 2018-10-19 2021-01-22 한남대학교 산학협력단 표면 개질된 다공성 탄소복합소재 및 그 제조방법
CN109912600B (zh) * 2019-02-22 2021-08-03 四川大学华西医院 一种防治肺纤维化的咪唑并嘧啶类衍生物及其应用
AU2021253243B2 (en) 2020-04-08 2024-01-18 Aptabio Therapeutics Inc. Agent for treating contrast-induced acute kidney injury
WO2021263281A2 (en) * 2020-06-26 2021-12-30 Ann And Robert H. Lurie Children's Hospital Of Chicago Methods and compositions for the treatment of covid-19 and associated respiratory distress and multi-organ failure, sepsis, acute respiratory distress syndrome, and cordiovascular diseases
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.

Also Published As

Publication number Publication date
MX2022012726A (es) 2022-11-07
KR20220039687A (ko) 2022-03-29
KR20210146871A (ko) 2021-12-06
BR112022020649A2 (pt) 2022-11-29
AU2021255160B2 (en) 2024-02-01
JP2023522628A (ja) 2023-05-31
US12616684B2 (en) 2026-05-05
CO2022014273A2 (es) 2022-10-21
AU2021255160A1 (en) 2022-10-06
CN115427039A (zh) 2022-12-02
EP4137134A1 (en) 2023-02-22
US20230148365A1 (en) 2023-05-11
CN115427039B (zh) 2025-04-04
JP7539485B2 (ja) 2024-08-23
CL2022002642A1 (es) 2023-06-16
EP4137134A4 (en) 2024-08-07
WO2021210799A1 (ko) 2021-10-21
KR102567012B1 (ko) 2023-08-14

Similar Documents

Publication Publication Date Title
JP7492002B2 (ja) Lsd1阻害剤によりlsd1関連疾患及び障害を治療する方法
KR102347721B1 (ko) 섬유성 질환의 치료에 사용하기 위한 ppar 화합물
JP7745584B2 (ja) 5’-アデノシン二リン酸リボース(adpr)の使用方法
KR102647942B1 (ko) 섬유증 치료제
EP4272832A2 (en) Antimicrobial compounds, compositions, and uses thereof
AU2021255160B2 (en) Pulmonary fibrosis medicine containing pyrazole derivative
KR20230121890A (ko) 섬유증 치료 방법
KR102386097B1 (ko) 피라졸 유도체의 폐섬유증 치료제
JP5457196B2 (ja) Cndac(2’−シアノ−2’−デオキシ−n4−パルミトイル−1−ベータ−d−アラビノフラノシル−シトシン)及び細胞毒性薬を含む組合せ
RU2817989C1 (ru) Средство для лечения фиброза легких, содержащее производное пиразола
JP7749661B2 (ja) 心不全の処置のためのクロマノール化合物
KR20210084442A (ko) 포도막 흑색종 치료를 위한 병용 요법
CN106999468B (zh) 熊脱氧胆酸和水飞蓟素改进cpt-11疗效和毒性的制药用途
EP1908473B1 (en) Clarithromycin or salt thereof for use in the treatment pulmonary emphysema
KR20220000460A (ko) 폐섬유화증 치료용 조성물
US20210260153A1 (en) Use of cyclosporine analogues for treating fibrosis
JPWO2002085363A1 (ja) 糸球体疾患治療剤
US10364230B2 (en) Chromene-2 derivatives and use thereof in the treatment of fibrosis
CN116270663A (zh) 胆汁酸及其衍生物在治疗呼吸道炎症性疾病中的应用
WO2020045475A1 (ja) ピラゾロ[3,4-d]ピリミジンの結晶
US20100179324A1 (en) Anti-tumor agent comprising sulphostin or sulphostin-related compound as the active ingredient
MX2007016109A (es) Claritromicina o sal de la misma para usarse en el tratamiento o prevencion de enfermedad pulmonar inducida por destruccion de los alveolos pulmonares.
HK1122209A (en) Clarithromycin or salt thereof for use in the treatment or prevention of pulmonary disease induced by destruction of pulmonary alveoli

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240829

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250614

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250614

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260310

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260321

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260323

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260326

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20260416

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260514

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260514